Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated November 21, 2025, reports a material legal development involving its subsidiary, TESARO, Inc. The filing addresses litigation initiated in the Delaware Chancery Court against AnaptysBio, Inc., concerning the license agreement for the oncology treatment Jemperli (dostarlimab).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on legal proceedings and product status rather than quantitative financial performance for the period.
Material Changes and Legal Developments
- Litigation Initiated: TESARO has sued AnaptysBio, alleging material breach of the March 2014 license agreement regarding Jemperli.
- Counter-Allegations: The lawsuit follows AnaptysBio's claim that TESARO failed to meet certain agreement requirements and AnaptysBio's intent to revoke TESARO's license.
- Requested Remedies: TESARO seeks to terminate the current agreement, obtain a perpetual and irrevocable license to dostarlimab, and reduce royalties and milestone payments to AnaptysBio by 50%.
- Management Position: GSK and TESARO assert that AnaptysBio's allegations are entirely without merit.
Outlook, Risks, and Product Commentary
Jemperli is currently approved in over 35 countries for certain endometrial cancers. GSK reports significant growth for the drug driven by label expansions in the US and EU. A clinical trial program is ongoing to evaluate dostarlimab for rectal, colon, and head and neck cancers. The filing includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" in GSK's 2024 Form 20-F and Q3 2025 results.
Investor Verification Checklist
- Verify the specific terms of the March 2014 license agreement between TESARO and AnaptysBio.
- Monitor the status of the Delaware Chancery Court litigation and any interim rulings.
- Assess the potential financial impact of a 50% reduction in royalties or the loss of the license on future cash flows.
- Review the "Risk Factors" section of GSK's 2024 Form 20-F for detailed legal and operational risks.
- Track the progress of Jemperli's clinical trials in new indications (rectal, colon, head and neck) to gauge future revenue potential independent of the dispute.